SIREN : 494760713
NEOVIX BIOSCIENCES is a French company founded 19 years ago, specialized in the sector Activités des sociétés holding. Based in LE PLESSIS-ROBINSON (92350), this company of category PME shows in 2022 a revenue of 728 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 727 715 € | 587 700 € | 538 162 € | 77 400 € | 28 080 € | 28 080 € |
| Net income | -582 680 € | -328 026 € | -466 152 € | -196 010 € | -170 876 € | -6 500 € |
| EBITDA | 15 259 € | 128 489 € | -9 562 € | -41 211 € | 12 029 € | 15 521 € |
| Net margin | -80.1% | -55.8% | -86.6% | -253.2% | -608.5% | -23.1% |
In 2022, NEOVIX BIOSCIENCES achieves revenue of 728 k€. Over the period 2017-2022, the company shows strong growth with a CAGR (compound annual growth rate) of +91.7%. Vs 2021, growth of +24% (588 k€ -> 728 k€). After deducting consumption (79 €), gross margin stands at 728 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 15 k€, representing 2.1% of revenue. Warning negative scissor effect: despite revenue change (+24%), EBITDA varies by -88%, reducing margin by 19.8 pts. This reflects costs rising faster than revenue. The operating margin remains fragile, requiring cost vigilance. Net income is negative at -583 k€ (-80.1% of revenue), which will impact equity.
727 715 €
727 636 €
15 259 €
-350 520 €
-582 680 €
2.1%
The debt ratio (= Financial debt / Equity x 100) stands at 3%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 93%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 21.3 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 0.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
2.618%
92.861%
0.718%
21.291
20.2%
In 2022, the debt ratio of NEOVIX BIOSCIENCES (2.62) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2022, the financial autonomy of NEOVIX BIOSCIENCES (92.9%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2022, the repayment capacity of NEOVIX BIOSCIENCES (21.29) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 779.73. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 4255.0x. Operating income very largely covers interest expenses: high safety margin.
779.731
4254.964
In 2022, the liquidity ratio of NEOVIX BIOSCIENCES (779.73) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2022, the interest coverage of NEOVIX BIOSCIENCES (4255.0x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 108 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 105 days. The company must finance 3 days of gap between collections and payments. Overall, WCR represents 635 days of revenue, i.e. 1.3 M€ to permanently finance. Over 2017-2022, WCR increased by +7201%, requiring additional financing.
1 283 769 €
108 j
105 j
0 j
635 j
Based on 70 transactions of similar company sales
in 2022,
the value of NEOVIX BIOSCIENCES is estimated at
205 330 €
(range 86 703€ - 373 727€).
With an EBITDA of 15 259€, the sector multiple of 2.4x is applied.
The price/revenue ratio is 0.67x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 70 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare NEOVIX BIOSCIENCES with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of NEOVIX BIOSCIENCES in 2022 is 728 k€.
NEOVIX BIOSCIENCES recorded a net loss in 2022.
The headquarters of NEOVIX BIOSCIENCES is located in LE PLESSIS-ROBINSON (92350), in the department Hauts-de-Seine.
The tax return of NEOVIX BIOSCIENCES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
NEOVIX BIOSCIENCES operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.